Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ImmunoPrecise Antibodies Ltd.
< Previous
1
2
Next >
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
March 16, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
March 07, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
December 15, 2022
From
IMMUNOPRECISE ANTIBODIES LTD.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
December 05, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
November 22, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
October 12, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
September 14, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
September 08, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
July 29, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
July 26, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
March 16, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
January 31, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
January 18, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 17, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 11, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 03, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
December 20, 2021
From
IMMUNOPRECISE ANTIBODIES LTD.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
December 13, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
December 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
November 30, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
November 24, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Resignation of Director
November 09, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
October 13, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
September 09, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
September 08, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
September 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
September 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
September 03, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
August 04, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
July 28, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.